NO994365L - Forutsigelse av koronararterie-sykdom - Google Patents

Forutsigelse av koronararterie-sykdom

Info

Publication number
NO994365L
NO994365L NO994365A NO994365A NO994365L NO 994365 L NO994365 L NO 994365L NO 994365 A NO994365 A NO 994365A NO 994365 A NO994365 A NO 994365A NO 994365 L NO994365 L NO 994365L
Authority
NO
Norway
Prior art keywords
coronary artery
artery disease
prediction
methods
patient
Prior art date
Application number
NO994365A
Other languages
English (en)
Other versions
NO994365D0 (no
Inventor
Sheila E Francis
David C Crossman
Gordon W Duff
Original Assignee
Medical Science Sys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Science Sys Inc filed Critical Medical Science Sys Inc
Publication of NO994365D0 publication Critical patent/NO994365D0/no
Publication of NO994365L publication Critical patent/NO994365L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det beskrives fremgangsmåter og tester for å forutsi en pasients risiko for en inflammatorisk forstyrrelse, så som koronararterie-sykdom eller relaterte vaskulære forstyrrelser. Fremgangsmåtene omfatter uttak av en biologisk prøve fra en pasient og bestemmelse av nærvær eller fravær av et bestemt allel som er forbundet med koronararterie-sykdom. Påvisning av allelet er indikativt for tilbøyelighet til utvikling av koronararterie-sykdom. Det beskrives også sett for påvisning av koronararterie- sykdom så vel som metoder for å identifisere ytterligere alleler som er assosiert med koronararterie-sykdom.
NO994365A 1997-03-10 1999-09-09 Forutsigelse av koronararterie-sykdom NO994365L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/813,456 US6210877B1 (en) 1997-03-10 1997-03-10 Prediction of coronary artery disease
PCT/US1998/004725 WO1998040517A1 (en) 1997-03-10 1998-03-09 Prediction of coronary artery disease

Publications (2)

Publication Number Publication Date
NO994365D0 NO994365D0 (no) 1999-09-09
NO994365L true NO994365L (no) 1999-11-09

Family

ID=25212420

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994365A NO994365L (no) 1997-03-10 1999-09-09 Forutsigelse av koronararterie-sykdom

Country Status (22)

Country Link
US (1) US6210877B1 (no)
EP (1) EP0983381B1 (no)
JP (2) JP4250765B2 (no)
CN (1) CN100523214C (no)
AR (1) AR011943A1 (no)
AT (1) ATE370246T1 (no)
AU (1) AU738875B2 (no)
BR (1) BR9808313A (no)
CA (1) CA2282746C (no)
DE (2) DE69838250T2 (no)
DK (1) DK0983381T3 (no)
EA (1) EA199900813A1 (no)
ES (1) ES2156843T3 (no)
GR (1) GR20010300016T1 (no)
IL (1) IL131745A0 (no)
MX (1) MXPA99008223A (no)
NO (1) NO994365L (no)
NZ (1) NZ337642A (no)
PL (1) PL335603A1 (no)
PT (1) PT983381E (no)
WO (1) WO1998040517A1 (no)
ZA (1) ZA981937B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210877B1 (en) * 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
US6720141B1 (en) 1999-11-01 2004-04-13 Interleukin Genetics, Inc. Diagnostics and therapeutics for restenosis
US6524795B1 (en) * 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
US7820383B2 (en) * 1997-03-10 2010-10-26 Interleukin Genetics, Inc. Method for diagnosing myocardial infarction
US20050282198A1 (en) * 1997-05-29 2005-12-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
US6437216B1 (en) 1997-11-13 2002-08-20 Interleukin Genetics Inc. Transgenic models of inflammatory disease
GB9723835D0 (en) * 1997-11-13 1998-01-07 Nicklin Martin Interleukin knockout
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US20050032077A1 (en) * 1998-03-10 2005-02-10 Duff Gordon W. Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6733967B1 (en) 1998-04-21 2004-05-11 Interleukin Genetics, Inc. Fetal testing for prediction of low birth weight
JP2002512047A (ja) * 1998-04-21 2002-04-23 インターリューキン ジェネティックス インコーポレイテッド 出生時低体重を予測するための胎児検査
US6251598B1 (en) 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
WO2000047619A1 (en) * 1999-02-10 2000-08-17 Interleukin Genetics, Inc. Therapeutics and diagnostics based on an il-1b mutation
ATE403746T1 (de) * 1999-05-24 2008-08-15 Interleukin Genetics Inc Diagnose von restenose
JP2003508022A (ja) * 1999-06-30 2003-03-04 インターリューキン ジェネティックス インコーポレイテッド Ｉｌ−１炎症性ハプロタイプと関連する病気の診断および治療方法
CN100424182C (zh) * 2001-06-15 2008-10-08 白介素遗传公司 衰老相关疾病早期发作的检测与治疗方法
US20080311581A1 (en) * 2001-11-19 2008-12-18 David Wyllie Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
KR101059898B1 (ko) * 2001-11-19 2011-08-29 인터레우킨 제네틱스, 인코포레이티드 염증성 질환 및 감염성 질환에 대한 감수성 및 전사에 영향을 미치는 인터루킨-1 좌의 기능적 다형성
EP1327639A1 (en) * 2002-01-15 2003-07-16 Bayer Ag Prediction of cardiovascular disease by genetic polymorphisms in cardiovascular associated genes
US20070264645A1 (en) * 2002-01-25 2007-11-15 Kenneth Kornman IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
KR100924468B1 (ko) * 2002-01-25 2009-11-03 인터레우킨 제네틱스, 인코포레이티드 Ｉｌ-1 유전자 집단 및 관련된 염증성 다형성과 일배체형
EP1549770B1 (en) * 2002-09-30 2008-03-12 Novartis AG Methods to predict cholesterol elevations during immunosuppressant therapy
US20050053956A1 (en) * 2002-11-13 2005-03-10 Dietz Harry C. Detection of a predisposition for the development of coronary artery disease
EP1592706A2 (en) * 2003-02-03 2005-11-09 Bayer HealthCare AG Genetic polymorphisms as predictive diagnostics for adverse drug reactions (adr) and drug efficacy
CA2518956A1 (en) * 2003-03-10 2004-09-23 Applera Corporation Single nucleotide polymorphisms associated with stenosis, methods of detection and uses thereof
JP2009523006A (ja) * 2004-05-07 2009-06-18 アプレラ コーポレイション 脈管疾患に関連する遺伝的多型、その検出方法および使用
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1951903A2 (en) * 2005-10-25 2008-08-06 Interleukin Genetics, Inc. The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes
US7935498B2 (en) * 2006-07-07 2011-05-03 Siemens Healthcare Diagnostics Inc. Methods for identifying patients with increased risk of an adverse cardiovascular event
US8101360B2 (en) * 2006-11-15 2012-01-24 Interleukin Genetics, Inc. IL-1 gene cluster, insulin resistance and coronary artery disease associated polymorphisms and haplotypes and methods of using same
EP2217725A2 (en) * 2007-11-08 2010-08-18 Interleukin Genetics, Inc. Diagnostics for aging-related dermatologic disorders
US20100112570A1 (en) * 2008-10-22 2010-05-06 Interleukin Genetics, Inc. Genetic Markers for Weight Management and Methods of Use Thereof
CN102747075B (zh) * 2012-06-07 2014-07-23 中国医学科学院阜外心血管病医院 与冠心病相关的6号染色体易感区域标签单核苷酸多态性位点及其组成的单体型与应用
JP2019503176A (ja) 2016-01-12 2019-02-07 インターロイキン ジェネティクス， インコーポレイテッド 処置に対する応答を予測するための方法
CN106202936A (zh) * 2016-07-13 2016-12-07 为朔医学数据科技（北京）有限公司 一种疾病风险预测方法及系统
US10329620B2 (en) 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
WO2020245402A1 (en) 2019-06-06 2020-12-10 Cardioforecast Ltd Compositions and methods for treating lung, colorectal and breast cancer
CN110277137B (zh) * 2019-06-13 2022-03-18 南方医科大学顺德医院(佛山市顺德区第一人民医院) 一种用于检测冠心病的基因芯片信息处理系统及方法
WO2021028469A1 (en) 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021205013A1 (en) 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US5110920A (en) 1982-01-22 1992-05-05 Cetus Corporation HLA typing method and DNA probes used therein
US4623619A (en) 1982-03-03 1986-11-18 Nordisk Insulinlaboratorium Method for the determination of liability in human individuals to develop atherosclerosis
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5268267A (en) 1987-08-21 1993-12-07 The General Hospital Corporation Method for diagnosing small cell carcinoma
GB9301453D0 (en) * 1993-01-26 1993-03-17 Clonit Spa Nucleotide proves
US5658729A (en) 1994-10-11 1997-08-19 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis
US5686246A (en) 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
US5698399A (en) 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis
US6210877B1 (en) * 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease

Also Published As

Publication number Publication date
ES2156843T1 (es) 2001-08-01
DE983381T1 (de) 2000-11-09
ZA981937B (en) 1999-09-06
BR9808313A (pt) 2000-05-16
JP4250765B2 (ja) 2009-04-08
PT983381E (pt) 2007-11-26
CA2282746C (en) 2009-02-24
EP0983381A4 (en) 2004-05-12
ATE370246T1 (de) 2007-09-15
NZ337642A (en) 2001-02-23
CA2282746A1 (en) 1998-09-17
CN100523214C (zh) 2009-08-05
NO994365D0 (no) 1999-09-09
JP2009077727A (ja) 2009-04-16
EP0983381B1 (en) 2007-08-15
GR20010300016T1 (en) 2001-04-30
EA199900813A1 (ru) 2000-06-26
IL131745A0 (en) 2001-03-19
ES2156843T3 (es) 2008-04-16
JP2001514522A (ja) 2001-09-11
AU738875B2 (en) 2001-09-27
PL335603A1 (en) 2000-05-08
MXPA99008223A (es) 2003-07-21
DE69838250T2 (de) 2008-05-08
CN1255948A (zh) 2000-06-07
AU6457498A (en) 1998-09-29
US6210877B1 (en) 2001-04-03
DE69838250D1 (de) 2007-09-27
WO1998040517A1 (en) 1998-09-17
DK0983381T3 (da) 2007-12-17
EP0983381A1 (en) 2000-03-08
AR011943A1 (es) 2000-09-13

Similar Documents

Publication Publication Date Title
NO994365L (no) Forutsigelse av koronararterie-sykdom
Kriek et al. Polycyclic aromatic hydrocarbon-DNA adducts in humans: relevance as biomarkers for exposure and cancer risk
EP1503213A3 (en) Detection and determination of the stages of coronary disease
AU4469300A (en) Nmr-method for determining the risk of developing type 2 diabetes
NO995803L (no) Forutsigelse av inflammatorisk sykdom assosiert med IL-1 genloki-polymorfisme
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
US20090011452A1 (en) Method of Prognosis of Mental Diseases, E.G. Autism and Cerebral Palsy
HK1184534A1 (zh) 通過測定半乳糖苷凝集素- 或者血小板反應蛋白- 的水平鑒定具有發生心力衰竭風險的受試者的方法
DK0947585T3 (da) Forbedret in vitro-fremgangsmåde, kits og reagenser til screening for blodkoagulationsdefekter
ATE524557T1 (de) Verbreiteter polymorphismus in scn5a, einhergehend mit durch medikamente induzierte herzarrythmien
Zinellu et al. Association between human plasma chondroitin sulfate isomers and carotid atherosclerotic plaques
EP1159614A4 (en) DIAGNOSTIC METHOD FOR ASTHMA
AU2002233800A1 (en) Method and kit for predicting cancer
ES2107528T3 (es) Ensayos de la actividad de la amilina.
CZ228898A3 (cs) Způsob určení stavu jaterních funkcí jedince, včetně u příjemce jaterního štěpu
US20110117584A1 (en) Detection of Chronic Kidney Disease Patients or Coronary Artery Disease Using Bone Morphogenic Protein-4
Kujovich et al. Factors V Leiden and the prothrombin gene mutation: two common genetic defects associated with thrombosis.
Kanttz et al. New state markers for alcoholism. Comparison of carbohydrate deficient transferrin (CDT) and alcohol mediated (triantennary) transferrin (AMT)
DE69912453D1 (de) Verfahren und materialien zur diagnose instabiler angina
AU5336796A (en) Method for detecting allergy
ES2225849T3 (es) Metodo para probar la capacidad inmunologica.
NO20082394L (no) Polypeptidmarkor for diagnostikk og vurdering av vaskulaere sykdommer
IL143639A0 (en) Method for determining the activity of a substance using a functional test in vitro
WO2003060161A3 (en) A method for assessing the potential responsiveness of a subject to anti-cancer drugs affecting the ras signal transduction pathway
Elmas et al. Lipoprotein complexed C-reactive protein in patients with coronary heart disease